Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Symptomatic treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,169 result(s) found for: Symptomatic treatment. Displaying page 1 of 109.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004494-96 Sponsor Protocol Number: BAY 59-7939/IMP 11899 Start Date*: 2007-03-19
    Sponsor Name:Bayer HealthCare AG
    Full Title: Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emb...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) DE (Completed) FI (Completed) FR (Completed) HU (Completed) AT (Completed) IT (Completed) DK (Completed) CZ (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004495-13 Sponsor Protocol Number: BAY 59-7939/11702 Start Date*: 2007-03-12
    Sponsor Name:Bayer Healthcare AG
    Full Title: Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.
    Medical condition: Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) SE (Completed) FR (Completed) DE (Completed) FI (Completed) DK (Completed) HU (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) NL (Completed) IE (Completed) LT (Completed) EE (Completed) LV (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002894-24 Sponsor Protocol Number: C4671006 Start Date*: 2021-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF-07321332/RITONAVIR IN PREVENTING SYMPTOMATI...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-003342-25 Sponsor Protocol Number: P170604J Start Date*: 2018-09-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis
    Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076654 Cancer-associated thrombosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002014-39 Sponsor Protocol Number: RTB-101-205 Start Date*: 2019-08-30
    Sponsor Name:resTORbio, Inc.
    Full Title: A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
    Medical condition: Clinically Symptomatic Respiratory Illness in the Elderly
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-005184-13 Sponsor Protocol Number: 50129 Start Date*: 2017-11-29
    Sponsor Name:MEDIOLANUM FARMACEUTICI S.P.A.
    Full Title: METRO STUDY - MESOGLYCAN VERSUS PLACEBO IN SECONDARY PREVENTION OF SURFACE VEIN THROMBOSIS
    Medical condition: patients with SVT of the lower limbs that have completed the acute phase treatment cycle
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001786-42 Sponsor Protocol Number: EFC6034 Start Date*: 2006-11-08
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfa...
    Medical condition: Patients with confirmed acute symptomatic pulmonary embolism with or without confirmed acute symptomatic deep vein thrombosis of the lower limbs.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) SK (Completed) SE (Completed) ES (Completed) BE (Completed) AT (Completed) DK (Completed) CZ (Completed) NL (Completed) EE (Completed) GR (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-003703-22 Sponsor Protocol Number: P2-IMU-838-UC Start Date*: 2018-05-03
    Sponsor Name:Immunic AG
    Full Title: A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe u...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) PL (Completed) PT (Completed) HR (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-004614-14 Sponsor Protocol Number: BAY 59-7939/12839 Start Date*: 2007-12-05
    Sponsor Name:Bayer HealthCare AG
    Full Title: MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin
    Medical condition: Prevention of venous thromboembolism in patients who have been hospitalized for a medical illness
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012108 Deep venous thrombosis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) DK (Completed) LT (Completed) GB (Completed) BE (Completed) AT (Completed) NL (Completed) ES (Completed) GR (Completed) PT (Completed) SI (Completed) SK (Completed) CZ (Completed) IT (Completed) PL (Completed) LV (Completed) FI (Completed) HU (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-004953-27 Sponsor Protocol Number: CV185-057 Start Date*: 2008-07-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm an...
    Medical condition: Venous Thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.0 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PT (Completed) GB (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001630-21 Sponsor Protocol Number: BAY59-7939/39039039STM4001/18262 Start Date*: 2015-12-15
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
    Medical condition: Venous thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001230-18 Sponsor Protocol Number: PRO-001 Start Date*: 2019-01-30
    Sponsor Name:Hellenic Genito-Urinary Cancer Group (HGUCG)
    Full Title: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients. A prospective, randomised, international multicentre, open-label, blinded-endpoint Phase III study. PRO...
    Medical condition: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005026-31 Sponsor Protocol Number: EFC6125 [AVE0005A/3001] Start Date*: 2006-04-24
    Sponsor Name:Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with ...
    Medical condition: pacientes con cáncer de ovario avanzado con ascitis maligna sintomática recurrente
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) HU (Completed) AT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014290-40 Sponsor Protocol Number: DU176b-D-U305 Start Date*: 2010-02-10
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar...
    Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004774-27 Sponsor Protocol Number: ART108053 Start Date*: 2007-03-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Comparison of ARIXTRA™ in lower LImb Superficial Thrombophlebitis with placebO (CALISTO). An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III...
    Medical condition: Superficial Thrombophlebitis (also known as superficial vein thrombosis)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042557 Superficial thrombophlebitis of leg LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) EE (Completed) HU (Completed) LV (Completed) GR (Completed) FR (Completed) SK (Completed) CZ (Completed) IT (Completed) GB (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002586-12 Sponsor Protocol Number: 1160.63 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Twice-daily oral direct thrombin inhibitor dabigatran in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embo...
    Medical condition: long-term prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatme...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) AT (Completed) IT (Completed) PL (Completed) CZ (Completed) NL (Completed) BE (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011013-24 Sponsor Protocol Number: AC-063A302 Start Date*: 2009-06-03
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symp...
    Medical condition: Indication: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002266-33 Sponsor Protocol Number: SATURN Start Date*: 2022-10-10
    Sponsor Name:BETH ISRAEL DEACONESS MEDICAL CENTER
    Full Title: STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS (SATURN)
    Medical condition: Intracerebral Hemorrhage (ICH) recurrence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000619-26 Sponsor Protocol Number: BAY59-7939/16416 Start Date*: 2014-06-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037439 Pulmonary thrombotic and embolic conditions HLT
    14.1 10047065 - Vascular disorders 10034572 Peripheral embolism and thrombosis HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) NL (Completed) NO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001954-40 Sponsor Protocol Number: SPh/01/2014 Start Date*: 2014-10-02
    Sponsor Name:SciencePharma spółka z ograniczoną odpowiedzialnością sp. k.
    Full Title: A randomized, multicenter, parallel, open-label study comparing the safety of the test investigational medicinal product (IMP) Enoxaparin Sodium 40 with the reference IMP Clexane for the prevention...
    Medical condition: Prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk knee surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 13:15:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA